Abbott to market Metra's bone markers:
This article was originally published in Clinica
Abbott is to develop and commercialise biochemical bone markers based on Metra Biosystems' technologies in a non-exclusive agreement. The deal, which will cover automated tests for metabolic bone and joint diseases, is worldwide, excluding Japan. Abbott will provide funding and instruments for the co-development of Metra's technologies on Abbott's automated systems. Metra will also receive revenue from royalties and rare reagent sales to Abbott.